A practical reference on alpha-MSH: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-18 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
== External links == International Chemical Safety Card 0578 NIOSH Pocket Guide to Chemical Hazards U.S. OSHA info on THF Archived 2017-05-02 at the Wayback Machine "2-Methyltetrahydrofuran, An alternative to Tetrahydrofuran and Dichloromethane". Sigma-Aldrich. Retrieved 2007-05-23.
Produced by Hilary Lawson, made by TVF Media 15 December Rheumatoid Arthritis, British scientists have discovered that sufferers lack a sugar in part of their immune system, namely the glycosylation of glycans on Immunoglobulin G (IgC); David Isenberg at Middlesex Hospital; the Pima tribe in Arizona, studied by British doctor Peter Bennett; the Hu Hu Kam Memorial Hospital in Sacaton, Arizona; Raymond Dwek researched glycobiology, how sugar molecules attached to the surface of cells; Tom Rademacher found that arthritis disappeared during pregnancy; Graham Rook, who researched microbiology at UCL, developed a biochemical test at Middlesex Hospital; people developed arthritis, in groups, across Lyme, Connecticut; Allen Steere of New England Medical Centre, who named Lyme disease.
== Signaling pathways == Induction of FPR triggers multiple changes in eukaryotic cells including rearrangement of the cytoskeleton which in turn facilitates cell migration and the synthesis of chemokines. Important FPR regulated pathways include:
Minor pathways may be specific to certain parts of plants; these can be either identical to the vertebrate pathway (including the GLO enzyme), or start with inositol and get to ascorbic acid via l-galactonic acid to l-galactonolactone.
Sources: en.wikipedia.org
Necrobiosis Lipoidica is a rare, chronic skin condition predominantly associated with diabetes mellitus (known as necrobiosis lipoidica diabeticorum or NLD). It can occur in individuals with rheumatoid arthritis or without any underlying conditions (idiopathic). It can also occur in patients with obesity, hypertension, celiac disease, and metabolic syndrome. Approximately a quarter of Necrobiosis Lipoidica cases are associated with diabetes mellitus. The broader overarching definition of necrobiosis is a gradual physiological death of a cell. It can be caused by basophilia, erythema, or a tumor. As a dermapathology term, it refers to altered collagen or altered dermal connective tissue. Necrobiosis Lipoidica is linked to microvascular damage and collagen degeneration. The exact cause of this condition is not known. It involves collagen degeneration and a granulomatous response in the layer of the skin called the dermis, often affecting the deeper fat layer and thickening dermal blood vessels. It is characterized by hardened, raised areas of the skin, often appearing on the shins, with a yellowish center and a surrounding dark pink area. The lesions are generally asymptomatic but can become tender and ulcerate when injured. Histological features and skin changes are caused by thickening of the blood vessel wall, collagen deterioration, granuloma (clustered white blood cells in tissues) formation, and fat deposits. Necrobiosis Lipoidica has many possible contributing factors, and research for treatment and causes is an ongoing process.
Vitamin or hormone supplements for what the body is lacking due to the disease (insulin, vitamin B12, thyroid hormone, etc.) Blood transfusions if the disease is blood related Physical therapy if the disease impacts bones, joints, or muscles Pharmaceutical treatment options include immunosuppressant drugs to reduce the immune response against the body's own tissues, such as:
=== Other appearances === Culp appeared in the 1993 live action video game Voyeur as the game's villain, industrialist/politician Reed Hawke. He lent his voice to the digital character Dr. Wallace Breen, the prime antagonist in the 2004 computer game Half-Life 2. The video clip of "Guilty Conscience" features Culp as an erudite and detached narrator describing the scenes where Eminem and Dr. Dre rap lyrics against each other. He only appears in the music video. In the album version, the narrator is Mark Avery. On November 9, 2007, on The O'Reilly Factor, host Bill O'Reilly interviewed Culp about the actor's career and awarded Culp with the distinction "TV Icon of the Week".
=== Immunization plan === People potentially exposed to rabies should discuss with a medical professional about risk assessment, namely the risk that the animal might be rabid, and about options for treatment, including about possible drug interactions, such as immunosuppressive medications. RIG (which provides immediate temporary passive immunity) should be given on the same day with the first rabies vaccine injection, or, if this is not possible, within a week after the first rabies vaccine.However, RIG should never be administered in the same syringe or in the same anatomical site as the first vaccine dose. RIG should not be given if more than a week has elapsed from the first dose of vaccine, after the second dose of vaccine or to people who are already partially immunized (such as people who had received PrEP) because this can interfere with their already existing antibodies. If a dog, cat or ferret is still alive and healthy (as certified by a professional) after 10 days from the exposure, then it could not have been infectious at the time of the exposure. However, in countries where rabies is common, the possibility of keeping the animal under observation should not lead to delay in the beginning of the treatment, because human rabies symptoms can occur as early as 7 days, and once symptoms have started the treatment is no longer effective. Instead, post-exposure prophylaxis should be started immediately after exposure, and it can subsequently be discontinued after 10 days, with the existing treatment functioning as PrEP for future exposure.
=== Pay-off phase === The second half of glycolysis is known as the pay-off phase, characterised by a net gain of the energy-rich molecules ATP and NADH. Since glucose leads to two triose sugars in the preparatory phase, each reaction in the pay-off phase occurs twice per glucose molecule. This yields 2 NADH molecules and 4 ATP molecules, leading to a net gain of 2 NADH molecules and 2 ATP molecules from the glycolytic pathway per glucose.
Sources: en.wikipedia.org
Different crystalline forms of an element are called allotropes. Some allotropes, particularly those of elements located (in periodic table terms) alongside or near the notional dividing line between metals and nonmetals, exhibit more pronounced metallic, metalloidal or nonmetallic behaviour than others. The existence of such allotropes can complicate the classification of the elements involved. Tin, for example, has two allotropes: tetragonal "white" β-tin and cubic "grey" α-tin. White tin is a very shiny, ductile and malleable metal. It is the stable form at or above room temperature and has an electrical conductivity of 9.17 × 104 S·cm−1 (~1/6th that of copper). Grey tin usually has the appearance of a grey micro-crystalline powder, and can also be prepared in brittle semi-lustrous crystalline or polycrystalline forms. It is the stable form below 13.2 °C and has an electrical conductivity of between (2–5) × 102 S·cm−1 (~1/250th that of white tin). Grey tin has the same crystalline structure as that of diamond. It behaves as a semiconductor (as if it had a band gap of 0.08 eV), but has the electronic band structure of a semimetal. It has been referred to as either a very poor metal, a metalloid, a nonmetal or a near metalloid. The diamond allotrope of carbon is clearly nonmetallic, being translucent and having a low electrical conductivity of 10−14 to 10−16 S·cm−1. Graphite has an electrical conductivity of 3 × 104 S·cm−1, a figure more characteristic of a metal.
== Personal life == Hird married Tania Poynton on 11 October 1997. Around the time of the marriage, Poynton was working as a lawyer at legal firm Corrs Chambers Westgarth, where she remained until 2002. The couple have since separated. Hird shares four children with Tania: a daughter and three sons. One of his sons, Thomas Hird, was signed as a category B rookie at Essendon in 2019 and was delisted by Essendon in 2022. Tom Hird now plays for the Port Melbourne Football Club in the Victorian Football League. Hird's paternal grandfather, the late Allan Hird, Sr., was a notable player for and president of the Essendon Football Club, and his father, Allan Hird, Jr., had a brief playing career with Essendon. Hird completed a bachelor's degree in civil engineering in 1998 and worked in that capacity as a consultant on the CityLink project. He has also spent time working for a stockbroking firm and is an active partner in Gemba, a sports marketing and media consultancy firm based in Melbourne. He is the founder and managing director of Euree Asset Management, where he currently works. On 5 January 2017, Hird was taken to a private hospital following a drug overdose and suspected suicide attempt and was subsequently transferred to a specialist mental health care facility for further care and treatment. On 28 November 2018, Hird was hit by a car when cycling in Richmond.
==== Binding site identification ==== Binding site identification is the first step in structure based design. If the structure of the target or a sufficiently similar homolog is determined in the presence of a bound ligand, then the ligand should be observable in the structure in which case location of the binding site is trivial. However, there may be unoccupied allosteric binding sites that may be of interest. Furthermore, it may be that only apoprotein (protein without ligand) structures are available and the reliable identification of unoccupied sites that have the potential to bind ligands with high affinity is non-trivial. In brief, binding site identification usually relies on identification of concave surfaces on the protein that can accommodate drug sized molecules that also possess appropriate "hot spots" (hydrophobic surfaces, hydrogen bonding sites, etc.) that drive ligand binding.
=== Ribosome-mediated attenuation === In this situation RNA polymerase is dependent on (lagging) ribosome activity; if the ribosome pauses due to insufficient charged tRNA then the anti-terminator structure is favoured. The canonical attenuator example of the trp operon uses this mechanism in E. coli. Similar regulatory mechanisms have been found in many amino acid biosynthetic operons.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.